High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI‐2) is an independent marker for shorter progression‐free survival in patients with early stage endometrial cancer

Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI‐2) and patient survival. High tumor tissue concentrations of PAI‐2 have been associated with good prognosis in patients with breast cancer, small cell lung cancer and ovarian cancer, but with poor histologic differentiation and poor prognosis in patients with colorectal cancer. On the other hand, high tumor tissue concentrations of urokinase plasminogen activator (uPA), uPA receptor (R) and PAI‐1 have more consistently been associated with poor histologic differentiation and poor prognosis. Our study quantified PAI‐2 and uPAR using specific enzyme‐linked immunosorbent assays in homogenates of 274 samples of endometrial cancer tissue. The prognostic power of each factor was analyzed in the subgroup of patients with early stage disease, i.e., International Federation of Gynecology and Oncology (FIGO) surgical stage I–II (n = 188). This group had a median follow‐up time of 6.8 years (range 0.7–9.9), and 23 progressions were observed. The 80th percentile for PAI‐2 and uPAR was used to dichotomize the material, and the results were analyzed for associations with clinical data including progression‐free survival. The results were also compared with DNA ploidy status, S‐phase fraction, uPA and PAI‐1, which we reported in a previous study (Fredstorp Lidebring et al., Eur J Cancer 2001; in press). A high PAI‐2 level was associated with shorter progression‐free survival in univariate analysis and was an independent prognostic factor in bivariate analyses, which included PAI‐1, uPA and DNA ploidy status. In contrast, a high level of uPAR had no association with prognosis in early stage endometrial cancer. The combination of high PAI‐2 and PAI‐1 levels in tumors revealed a small group of stage I–II patients with an accumulative progression rate of 50%. © 2001 Wiley‐Liss, Inc.

[1]  K. Tsuchihara,et al.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer , 1996, Virchows Archiv.

[2]  N. Brünner,et al.  The urokinase plasminogen activator system as a target for prognostic studies in breast cancer , 2004, Breast Cancer Research and Treatment.

[3]  N. Brünner,et al.  Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. , 2001, European journal of cancer.

[4]  J. Vassalli,et al.  Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. , 2001, Cancer research.

[5]  D. Doering,et al.  Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. , 2001, Gynecologic oncology.

[6]  N. Brünner,et al.  The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. , 2000, Cancer research.

[7]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[8]  A. Jhingran,et al.  Indications for adjuvant radiotherapy in endometrial carcinoma. , 1999, Hematology/oncology clinics of North America.

[9]  C. Borgfeldt,et al.  High tissue content of urokinase plasminogen activator (u‐PA) is associated with high stromal expression of u‐PA mRNA in poorly differentiated serous ovarian carcinoma , 1998, International journal of cancer.

[10]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[11]  B. Gustavsson,et al.  Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u‐PA, t‐PA) in endometrial carcinoma , 1998, International journal of cancer.

[12]  A. Gadducci,et al.  An analysis of approaches to the management of endometrial cancer in North America: a CTF study. , 1998, Gynecologic oncology.

[13]  O. Yoshida,et al.  Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy , 1998, International journal of cancer.

[14]  M. Carcangiu,et al.  Expression of plasminogen activator inhibitor‐2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF‐1 , 1997, International journal of cancer.

[15]  T. Hattori,et al.  Cellular localization of urokinase‐type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues , 1997, The Journal of pathology.

[16]  H. Nielsen,et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. , 1997, Clinical chemistry.

[17]  F. Jänicke,et al.  Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. , 1997, Gynecologic oncology.

[18]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[19]  M. Duffy,et al.  Plasminogen activator inhibitor type 2 in breast cancer. , 1997, British Journal of Cancer.

[20]  B. Casslén,et al.  Plasminogen activator inhibitor 2 in menstrual endometrium and in primary cultures of endometrial cells , 1996 .

[21]  M. Fernö,et al.  Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. , 1996, European journal of cancer.

[22]  David Machin,et al.  Survival Analysis: A Practical Approach , 1995 .

[23]  A. Gadducci,et al.  An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. , 1995, European journal of cancer.

[24]  R. Gertz,et al.  The significance of urokinase‐type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer , 1995, Cancer.

[25]  J. Foekens,et al.  Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. , 1995, Cancer research.

[26]  T. Hattori,et al.  Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer , 1995, Japanese journal of cancer research : Gann.

[27]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[28]  C. V. D. van de Velde,et al.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. , 1994, Cancer research.

[29]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[30]  T. Högberg,et al.  Identification of small areas of solid growth has a strong prognostic impact in differentiated endometrial carcinomas. A histopathologic and morphometric study , 1994, International Journal of Gynecologic Cancer.

[31]  T. Urano,et al.  Plasminogen activators and their inhibitors in non‐small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination , 1994, Cancer.

[32]  F. Spyratos,et al.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. , 1994, British Journal of Cancer.

[33]  B. Casslén,et al.  Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. , 1994, European journal of cancer.

[34]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[35]  J. Bonnar,et al.  The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. , 1992, Gynecologic oncology.

[36]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[37]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[38]  S. Wingren,et al.  Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator. , 1989, Gynecologic oncology.

[39]  Richard K. Reznick,et al.  Survival analysis: A practical approach , 1989, Diseases of the colon and rectum.

[40]  M. Fernö,et al.  Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation. , 1987, Anticancer research.

[41]  D. Belin,et al.  Plasminogen activator-specific inhibitors produced by human monocytes/macrophages , 1987, The Journal of experimental medicine.

[42]  B. Åstedt,et al.  Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma , 1986, British journal of haematology.

[43]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[44]  E. Davis.  CARCINOMA OF THE CORPUS UTERI. , 1964, American journal of obstetrics and gynecology.

[45]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.